The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the BioLineRx Ltd stock forecast from 1 analysts, the average analyst target price for BioLineRx Ltd is USD 2.00 over the next 12 months. BioLineRx Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioLineRx Ltd is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, BioLineRx Ltd’s stock price was USD 0.6136. BioLineRx Ltd’s stock price has changed by -5.15% over the past week, -11.16% over the past month and -74.64% over the last year.
No recent analyst target price found for BioLineRx Ltd
No recent average analyst rating found for BioLineRx Ltd
Company Overview BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Read Less
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, an...Read More
Frequently Asked Questions About BioLineRx Ltd (BLRX) Stock
Based on ratings from 1 analysts BioLineRx Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BLRX is USD 2.00 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on BLRX's stock to indicate if its overvalued.
The last closing price of BLRX's stock was USD 0.61.
The most recent market capitalization for BLRX is USD 0.05B.
Based on targets from 1 analysts, the average taret price for BLRX is projected at USD 2.00 over the next 12 months.
This means that BLRX's stock price may go up by +225.95% over the next 12 months.
We can't find any ETFs which contains BioLineRx Ltd's stock.
As per our most recent records BioLineRx Ltd has 79 Employees.
BioLineRx Ltd's registered address is Modi?in Technology Park, Hevel Modi'in, Israel, 7177871.
You can get more information about it from BioLineRx Ltd's website at https://www.biolinerx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About BioLineRx Ltd (BLRX) Stock
Based on ratings from 1 analysts BioLineRx Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BLRX is USD 2.00 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on BLRX's stock to indicate if its overvalued.
The last closing price of BLRX's stock was USD 0.61.
The most recent market capitalization for BLRX is USD 0.05B.
Based on targets from 1 analysts, the average taret price for BLRX is projected at USD 2.00 over the next 12 months.
This means that BLRX's stock price may go up by +225.95% over the next 12 months.
We can't find any ETFs which contains BioLineRx Ltd's stock.
As per our most recent records BioLineRx Ltd has 79 Employees.
BioLineRx Ltd's registered address is Modi?in Technology Park, Hevel Modi'in, Israel, 7177871.
You can get more information about it from BioLineRx Ltd's website at https://www.biolinerx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
